Introduction

Effective Antithrombin III deficiency treatment often requires clinicians to look beyond standard systemic protocols. This rare thrombophilic disorder frequently leads to resistance against systemic thrombolytic therapy. Consequently, medical teams must identify alternative strategies when initial treatments fail to resolve massive clots. A recent case report highlights the successful use of catheter-directed thrombolysis (CDT) as a rescue therapy for patients facing this clinical challenge.

Clinical Presentation and Systemic Failure

A previously healthy 33-year-old man presented with acute dyspnoea and severe left-leg swelling. Diagnostic imaging confirmed bilateral pulmonary artery thrombi and extensive iliofemoral deep-vein thrombosis (DVT). Furthermore, the patient exhibited signs of acute right-ventricular failure. Initially, doctors administered a systemic alteplase infusion to address the high-risk pulmonary thromboembolism. However, thrombus resolution remained incomplete despite the therapy. Laboratory testing subsequently revealed a hereditary Antithrombin III (AT III) deficiency, with activity levels measured at only 53%.

The Role of CDT in Antithrombin III Deficiency Treatment

Because systemic treatment proved inadequate, the medical team initiated catheter-directed thrombolysis via the right femoral vein. They delivered alteplase directly into the thrombus site at a precise dose of 0.02 mg/kg/h over 48 hours. This targeted Antithrombin III deficiency treatment achieved near-complete resolution of the massive DVT and restored venous flow. Moreover, the patient experienced no bleeding complications during the intervention. This case demonstrates that CDT provides a high local concentration of fibrinolytic agents. Specifically, it can overcome the massive thrombotic burden often seen in patients with underlying AT III deficiency.

Conclusion

Early recognition of hereditary thrombophilias is vital when patients show poor response to standard thrombolytics. Specifically, CDT serves as an effective, low-risk rescue intervention for extensive DVT when systemic treatment is inadequate. Clinicians should consider catheter-based interventions early in high-risk settings to optimize patient outcomes and restore hemodynamic stability.

Frequently Asked Questions

Why does Antithrombin III deficiency cause resistance to thrombolytic therapy?

Antithrombin III is a natural anticoagulant and a necessary cofactor for many blood thinners. In deficient states, the body remains in a highly prothrombotic state. While thrombolytics like alteplase work on existing fibrin, the ongoing clotting process may outpace systemic drug concentrations, leading to therapeutic failure.

Is CDT safer than systemic thrombolysis for DVT?

CDT allows for a lower total dose of thrombolytic medication delivered directly to the clot. Consequently, it often carries a lower risk of systemic bleeding complications while providing higher local efficacy for extensive iliofemoral thrombi.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional physician-patient relationship. Always seek the advice of a qualified healthcare provider for any medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Son BJ et al. Systemic Thrombolytic Resistance in Antithrombin III Deficiency Rescued by Catheter-Directed Thrombolysis: A Case Report. Catheter Cardiovasc Interv. 2026 Mar 24. doi: 10.1002/ccd.70569. PMID: 41876387.

Thachil J. Antithrombin: and its role in disease and therapy. Blood Reviews. 2016;30(3):175-181.

Jaff MR et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011;123(16):1788-1830.